Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 8/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | TEK | Q02763 | 1/20 | 0.39 |
| ▸ | CBFB | Q13951 | 1/20 | 0.38 |
| ▸ | BUB1 | O43683 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6832626 | 0.88 | TGFBR1 (0.40) | TGFBR1KDRTEKCBFBMAPK8 | |
| SCHEMBL6832965 | 0.85 | KCNN1 (0.44) | TGFBR1GRM4PIK3CAMEN1KMT2A | |
| SCHEMBL6832036 | 0.85 | IGF1R (0.43) | TGFBR1CBFBBUB1 | |
| SCHEMBL6832462 | 0.81 | KDM4E (0.44) | TGFBR1MAPK10MEN1KMT2A | |
| SCHEMBL6832525 | 0.81 | TGFBR1 (0.54) | TGFBR1MEN1KMT2A | |
| SCHEMBL6829358 | 0.81 | TGFBR1 (0.44) | TGFBR1MAPK10MEN1KMT2A | |
| SCHEMBL6832624 | 0.81 | BUB1 (0.40) | TGFBR1BUB1MAPK8MAPK10ABCB1 | |
| SCHEMBL6834538 | 0.79 | TGFBR1 (0.47) | TGFBR1MAPK10ABCB1ABCG2MEN1 | |
| SCHEMBL6832969 | 0.79 | GRM4 (0.42) | TGFBR1GRM4MAPK10MEN1TSHR | |
| SCHEMBL6832044 | 0.79 | NR4A1 (0.43) | TGFBR1MAPK8MAPK10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097502-A1 | Pyrazoles as tgf inhibitors | GELLIBERT FRANCOISE JEANNE (FR) | 2004-05-20 | — | — | US | claimed |
| EP-1363904-A1 | PYRAZOLES AS TGF INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | claimed |
| WO-2002062787-A1 | PYRAZOLES AS TGF INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-08-15 | — | — | WO | claimed |
| US-20040097502-A1 | Pyrazoles as tgf inhibitors | GELLIBERT FRANCOISE JEANNE (FR) | 2004-05-20 | — | — | US | disclosed |
| EP-1363904-A1 | PYRAZOLES AS TGF INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002062787-A1 | PYRAZOLES AS TGF INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097502-A1 | Pyrazoles as tgf inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885KDR 1298/4885TEK 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.